Treatment
Car-t clinical trials
We’re tracking 422 recruiting studies that include Car-t, each written for real people, not researchers, below.
Recruiting studies
- NCT07715630RecruitingPhase 1
PICX CAR-T therapy for relapsed or hard-to-treat multiple myeloma
This trial tests a new treatment called PICX CAR-T, a type of immune cell therapy, for multiple myeloma that has come back or not responded well to at least two prior treatments. It aims to see if this therapy can help control the disease.
Kunming, YunnanAges 18 years+ - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07274059RecruitingEarly Phase 1
CAR-T cell therapy from cord blood for lupus
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
Yancheng, JiangsuAges 18–75 - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+ - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07475182RecruitingEarly Phase 1
Cell therapy for advanced solid tumors with specific proteins
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Haikou, HainanAges 18–75 - NCT06676982RecruitingPhase 1
CAR-T cell therapy for advanced liver cancer
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
Hangzhou, ZhejiangAges 18–80 - NCT07528105RecruitingEarly Phase 1
CAR-T Cell Therapy for Early-Stage Type 1 Diabetes
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
ShanghaiAges 18–40 - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06352281RecruitingPhase 1/Phase 2
CAR-T cell therapy for chronic or hard-to-treat ITP
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Kunming, YunnanAges 8–75 - NCT05947487RecruitingPhase 1/Phase 2
CAR-T treatment for CD70-positive advanced solid tumors
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Beijing, Iotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT05827835RecruitingPhase 1/Phase 2
CD7 CAR-T treatment then stem cell transplant for CD7 leukemia
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
Hangzhou, ZhejiangAges 18 years+ - NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT07586709RecruitingEarly Phase 1
CAR-T cell therapy targeting BCMA and GPRC5D for advanced plasma cell cancers
This trial is testing a new type of cell therapy that uses your own immune cells (called CAR-T cells) to fight your cancer. The cells are modified to attack two specific targets on your cancer cells (BCMA and GPRC5D) to potentially improve treatment response.
BeijingAges 18–75 - NCT07359014Recruiting
Dual-target car-t cell therapy for multiple myeloma
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
HangzhouAges 18–75 - NCT07524816Recruiting
CAR-T Cell Therapy for Relapsed Lymphoma
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
Lyasny, Minsk OblastAges 18–80 - NCT07489534RecruitingPhase 2
CAR-T therapy for multiple myeloma with kidney problems
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT06866873Recruiting
CAR-T cell therapy for kids with ALL or lymphoma
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hong KongAges 1–17 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06644443RecruitingPhase 1/Phase 2
BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Shenzhen, GuangdongAges 18–75 - NCT05240950RecruitingPhase 1
CAR-T cell therapy for colorectal cancer in the liver
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75
Common questions
- Are there clinical trials studying Car-t?
- Yes. Clin2 currently lists 422 recruiting studies that include Car-t, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Car-t trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Car-t an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Car-t or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.